Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the

Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Arvinas, Inc. (N

Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC pla

Evercore ISI Group analyst Jonathan Miller maintains Arvinas (NASDAQ:ARVN) with a Outperform and

Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the pri

Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about

Arvinas (NASDAQ: ARVN) said it is concentrating resources on its early-stage oncology and neurology

Wells Fargo analyst Derek Archila downgrades Arvinas (NASDAQ:ARVN) from Overweight to Equal-Weigh

Wedbush analyst Robert Driscoll maintains Arvinas (NASDAQ:ARVN) with a Neutral and raises the pri

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pi

Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensu

Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the

Arvinas (NASDAQ:ARVN) reported quarterly earnings of $2.58 per share which beat the analyst consensu

– Secured the first-ever regulatory approval of a PROTAC (a type of  heterobifunctional protein degr

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology co

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat

Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted

Stephens & Co. analyst Sudan Loganathan reiterates Arvinas (NASDAQ:ARVN) with a Overweight an

Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its

NEW HAVEN, Conn. , May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage b

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage bi

Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Phar

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including

Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is enteri

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer fol

Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensi

Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted

Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment fo

U.S.